PubMed Health⌕ Search

Biomedical subjects

T Modena

Publications and source records attributed to T Modena.

At least 19 recordsLinked to original sources

Biodegradable microspheres for prolidase delivery to human cultured fibroblasts.

Prolidase deficiency (PD) is a rare autosomal recessive disorder caused by inadequate levels of the cytosolic exopeptidase prolidase (E.C. 3.4.13.9), for which there is not, as yet, a resolutive cure. We have investigated whether biodegradable microspheres loaded with prolidase could release active enzyme inside cells, to consider this system as a possible therapeutic approach for prolidase deficiency. Poly(lactide-co-glycolide) microspheres were prepared, modifying the classical double emulsion solvent evaporation method to mitigate the burst effect of the enzyme from the microspheres. Ex-vivo experiments were performed, by incubating microencapsulated prolidase with cultured fibroblasts from PD patients and from controls, to determine the amount of active enzyme delivered to the cells. The microparticulate drug delivery system described carried small amounts of active prolidase inside fibroblasts, ensuring a response to the intracellular accumulation of X-Pro dipeptides, the mechanism that is supposed to be responsible for the development of clinical manifestations of this disorder in man. A positive result of the presence of active enzyme inside cells was an improvement in fibroblast shape.

Biodegradation, Environmental↗

PLGA microspheres for oral osteopenia treatment: preliminary "in vitro"/"in vivo" evaluation.

The aim of this work was to prepare and to evaluate "in vitro"/"in vivo" microspheres based on poly(D,L-lactide-co-glycolide) copolymers containing ipriflavone, for the local treatment of oral bone loss. The first objective was the preparation and "in vitro" characterization of ipriflavone loaded microspheres, by emulsion/solvent evaporation method. Process parameters such as drug:polymer weight ratio, and molecular weight of copolymers, were also investigated. The second objective was to elaborate a suitable animal model of mandibular osteoporosis, to evaluate the efficacy of these microparticulate drug delivery systems. "In vivo" experiments were carried out on female rats, in which oral osteopenia was induced by gonadectomy and molar avulsion. Morphometric analysis of mandibular segment were carried out to quantify the development of oral osteopenia and the efficacy of drug loaded microspheres. Results showed that ipriflavone loaded PLGA microspheres can be successfully obtained with good "in vitro" characteristics, utilizing the emulsification/solvent evaporation method. "In vivo" experiments revealed that local administration of microspheres produced only mild inflammation on the injection site. Morphometric analyses showed, at the level of the third molar, a slight increase in spongy and total bone mass on rat jaw treated with microspheres with respect to control. Control animals exhibited a scarce degree of osteopenia demonstrating that this animal model is not suitable for this purpose.

Animals↗

Periodontal delivery of ipriflavone: new chitosan/PLGA film delivery system for a lipophilic drug.

The aim of the present work was to design a film dosage form for sustained delivery of ipriflavone into the periodontal pocket. For this purpose, monolayer composite systems made of ipriflavone loaded poly(D,L-lactide-co-glycolide) (PLGA) micromatrices in a chitosan film form, were obtained by emulsification/casting/evaporation technique. Multilayer films, made of three layers of polymers (chitosan/PLGA/chitosan), were also prepared and compared to monolayer films for their "in vitro" characteristics. Morphology and physico-chemical properties of the different systems were evaluated. The influence of pH, ionic strength and enzymatic activity on film degradation, was also investigated. Significant differences in swelling, degradation and drug release were highlighted, depending on film structure and composition. In vitro experiments demonstrated that the composite micromatricial films represent a suitable dosage form to prolong ipriflavone release for 20 days.

Chitin↗

Effect of nanoparticle encapsulation on the photostability of the sunscreen agent, 2-ethylhexyl-p-methoxycinnamate.

The aim of this study was to investigate the influence of nanoparticle-based systems on the light-induced decomposition of the sunscreen agent, trans-2-ethylhexyl-p-methoxycinnamate (trans-EHMC). Ethylcellulose (EC) and poly-D,L-lactide-co-glycolide (PLGA) were used as biocompatible polymers for the preparation of the particulate systems. The "salting out" method was used for nanoparticle preparation and several variables were evaluated in order to optimize product characteristics. The photodegradation of the sunscreen agent in emulsion vehicles was reduced by encapsulation into the PLGA nanoparticles (the extent of degradation was 35.3% for the sunscreen-loaded nanoparticles compared to 52.3% for free trans-EHMC) whereas the EC nanoparticle system had no significant effect. Therefore, PLGA nanoparticles loaded with trans-EHMC improve the photostability of the sunscreen agent.

Cellulose↗

Enzyme loaded biodegradable microspheres in vitro ex vivo evaluation.

Prolidase is a naturally occurring enzyme involved in the final stage of protein catabolism. Deficient enzyme activity causes prolidase deficiency (PD), a rare autosomal recessive inherited disorder whose main manifestations are chronic, intractable ulcerations of the skin, particularly of lower limbs. Although several attempts have been made towards the treatment of this pathology, a cure for this disease has yet to be found. The purpose of this work is to evaluate the possibility of enzyme replacement therapy through prolidase microencapsulation in biodegradable microspheres. The poly(D,L-lactide-co-glycolide) (PLGA) prolidase loaded microparticulate systems have been prepared utilizing the w-o-w double emulsion solvent evaporation method. They have been characterized "in vitro" by morphological analysis, total protein content and an in vitro dissolution test of active protein. "Ex vivo" evaluation of prolidase activity from the microspheres has been performed on cellular extracts of cultured skin fibroblasts from healthy subjects (controls) and from patients affected by PD. The results reported in this work on prolidase from pig kidney (available on the market) demonstrate the positive role of microencapsulation as a process of enzymatic activity stabilization inside PLGA microspheres achieving both in vitro and ex vivo active enzyme release. This formulation can be proposed as a parenteral depot drug delivery system.

Adult↗

Long-term release of clodronate from biodegradable microspheres.

This paper describes the formulation of a biodegradable microparticulate drug delivery system containing clodronate, a bisphosphonate intended for the treatment of bone diseases. Microspheres were prepared with several poly(D,L-lactide-co-glycolide) (PLGA) copolymers of various molecular weights and molar compositions and 1 poly(D,L-lactide) (PDLLA) homopolymer by a water-in-oil-in-water (w/o/w) double emulsion solvent evaporation procedure. Critical process parameters and formulation variables (ie, addition of stabilizing agents) were evaluated for their effect on drug encapsulation efficiency and clodronate release rate from microparticles. Well-formed clodronate-loaded microspheres were obtained for all polymers by selecting suitable process parameters (inner water/oil volume ratio 1:16, temperature-raising rate in the solvent evaporation step 1 degree C/min, 2% wt/vol NaCl in the external aqueous phase). Good yields were obtained in all batches of clodronate microspheres (above 60%); drug encapsulation efficiencies ranged between 49% and 75% depending on the polymer used. Clodronate release from all copolymer microspheres was completed in about 48 hours, while those from PDLLA microspheres required about 20 days. The change of microsphere composition by adding a surfactant such as Span 20 or a viscosing agent such as carboxymethylcellulose extended the long-term release up to 3 months. Clodronate was successfully entrapped in PLGA and PDLLA microspheres, and drug release could be modulated from 48 hours up to 3 months by suitable selection of polymer, composition, additives, and manufacturing conditions.

Biodegradation, Environmental↗

Microparticulate drug delivery systems.

Chitosan was proposed as a drug carrier for mucosal administration in ocular, buccal, nasal, gastroenteric and vaginal-uterine therapies based on its bioadhesive properties and biodegradability in vivo under the action of hydrolases. Examples are the delivery of acyclovir via ocular administration, and the delivery of 5-aminosalicylic acid to the colon. Microparticles may need to be cross-linked to retard their degradation in acidic media; yet cross-linking with glutaraldehyde introduces cytotoxic characteristics and depresses bioadhesion. Alternative cross-linking approaches are discussed along with the suitability of chitosan for the oral delivery of vaccines.

Acyclovir↗

[The regulation of drug prices in Italy].

Medicinal products price regulation in Italy has been discussed. The financial law n. 537/93 has deeply modified the criteria utilised to define the industrial medicaments prices. The authors analysed the implications derived from the variation from a fixed price system to a system based on the media of the european drug prices.

Drug Costs↗

Antigravitropic activity of 2-(2-arylamino-1,2-dioxoethyl) benzoic acid methyl esters.

Methylation of 1,3-dihydro-1-hydroxy-3-oxo-1-isobenzofurancarboxamides (A-I) yields 2-(2-arylamino-1,2-dioxoethyl)benzoic acid methylesters. The esters 1-7 allowed the evaluation of the intrinsic activity of 2-(2-arylamino-1,2-dioxoethyl)benzoic structure, to whom the antigravitropic effect of the carboxamides A-I may be probably assigned. The comparison of activities of methylesters 1-7 (B) and 8-14 (C) shows how conformational differences as those between the arylamino-1,2-dioxoethylic portion of B and the arylamino-2-oxoethylic portion of C may deeply effect phytotropin interaction with the receptor site.

Benzoates↗

Antimycotic 2-alkyldithio, 2-aralkyldithio, 2-aryldithiobenzamides.

Some 2-alkyldithio, 2-aralkyldithio, 2-aryldithio benzoic acids, their methyl esters and N-monosubstituted amides were prepared and tested in vitro against Candida albicans and Trichophyton mentagrophytes. Some N-monosubstituted amides displayed activities similar to those of clotrimazole and pyrrolnitrin. Against Candida albicans, N-monosubstituted amides exhibited a generally higher activity than the corresponding N-monosubstituted amides of 2,2'-dicarboxydiphenyldisulfide.

Amides↗

[Derivatives of 2-thiocyanobenzoic acid with antifungal activity].

A series of amides, esters and thioesters of 2-thiocyanobenzoic acid were synthesised and tested for antifungal activity in vitro and in vivo against various strains of fungus pathological to plants. The phytotoxicity against representative plants was studied in parallel. The substances were prepared by condensation of suitable mercaptobenzamides with cyanogen bromide or of 2-thiocyanobenzoyl chloride with amines, alcohols or mercaptans. This research showed in vitro antifungal activity of some N-monosubstituted amides and in vivo activity of some N-monosubstituted and N,N-disubstituted amides of 2-thiocyanobenzoic acid which have the same protective activity towards P. viticola as Zineb.

Animals↗

[Anticryptogamic activity of some aryl esters of N-benzyldithiocarbamic acid].

Some aryl esters of N-benzyldithiocarbamic acid, characterized by the presence on the S-aryl group of hydrophilic or potentially hydrophilic groups were studied for anticryptogamic activity in vitro and in vivo. The substances were prepared by condensation of benzylisothiocyanate with suitable benzenethiols. The results showed the anticryptogamic activity of acylation derivatives of N-monosubstituted thiosalicylamides with the acyl of N-benzylthiocarbamic acid.

Animals↗

[Aryl esters of N-benzyldithiocarbamic acid with antimycotic activity].

Some aryl esters of N-benzyldithiocarbamic acid [substances (I leads to XVI)], in which S aryl substituents were hydrophylic or potentially hydrophylic groups, were tested for in vitro antifungal activity against the following strains: Candida albicans, Saccharomyces cerevisiae and Trichophyton mentagrophytes. The substances were prepared by condensation of benzylisothiocyanate with suitable benzenethiols. The results, given in Table I, show the marked activity as antifungal agents of the N-benzyldithiocarbamic acid aryl esters studied; the antifungal activity, connected with the N-benzyldithiocarbamic group, is only slightly influenced by the nature of the substituents.

Antifungal Agents↗

[Benzenedithiol esters with antimycotic activity].

Some diesters of benzen-1,2-dithiol wit aliphatic and aromatic carboxylic acids were prepared and tested for in vitro antifungal activity. The diacetate and dipropionate of benzen-1,3- and 1,4-dithiol were used as comparison compounds. The substances (Table I; substances I leads to X) were obtained by condensation of benzenedithiols with suitable acylating agents. The fungistatic activity of the products was tested in vitro against the following fungal strains: Candida albicans, Candida tropicalis, Saccharomyces cerevisiae and Trichophyton mentagrophytes. The results show that the diester of benzen-1,2-dithiols with alkanoic acids (Table I) have marked antimycotic activity, much greater than that of clotrimazol. The diaroyl esters of benzen-1,2-dithiol and the diesters of benzen-1,3- and 1,4-dithiols are inactive or only slightly active.

Antifungal Agents↗

[Acaricidal, chemosterilant and insecticidal activity of triazine derivatives].

A large number of 1-aryl-3,3-dialkyl triazenes and 1,2-diphenyl triazenes variously substituted in the 3 position with OH and alkyl groups were prepared and studied for acaricide activity against Panonychus ulmi and chemosterilizing and insecticidal activity against Musca domestica. The results highlighted the marked chemosterilizing activity of 1-(2-methoxyphenyl)-3,3-di-n-propyltriazene and the interesting acaricidal activity of 1-(4-benzoylphenyl)-3,3-dimethyltriazene. The examination of such a large number of compounds for insecticidal activity allowed interesting conclusions to be drawn regarding structure/activity relationships.

Acari↗

[Antifungal activity of diesters of 2-mercaptobenzene methanethiol].

Some diesters of 2-mercaptobenzenmethanthiol and of 2-(2-nitrophenyl)-1,3-benzodithiyne were prepared and tested for in vitro antifungal activity. The substances [Table I: substances (I leads to VIII)] were obtained by condensation of 2-mercaptobenzenmethanthiol with suitable reagents. The antifungal activity of the products was tested in vitro against the following strains: Candida albicans, Saccharomyces cerevisiae and Trichophyton mentagrophytes. It was found that antimycotic activity is shown by only some of the diesters of 2-mercaptobenzenmethanthiol with acyl alkylthiocarbamic groups (Table I). The diesters with aliphatic, aromatic, alkylcarbamic groups and the 2-(2-nitrophenyl)-1,3-benzodithiyne are inactive or only slightly active.

Antifungal Agents↗

[Preparation and study of the antimycotic activity of 2-substituted 1,3-benzodithiols].

A series of 1,3-benzodithiols substituted at position 2, obtained by condensation of benzene 1,2-dithiols with aldehydes and ketones, was studied for antifungal activity. The fungistatic activity of the compounds [Table I, II; (I leads to XXV)] was tested in vitro against the four strains: Candida albicans, Candida tropicalis, Saccharomyces cerevisiae and Trichophyton mentagrophytes. The results indicate at the 2-monosubstituted 1,3-benzodithiols are an interesting class of antifungal substances, the 2-phenyl substituted derivative (1) being of particular interest.

Antifungal Agents↗